-2.6% of which Eastern Europe and Turkey
-0.8% of which Asia
+7.7% of which Latin America(1)
-15.9% of which Africa
+9.9% of which Middle East
+5.9%Rest of the world***977+9.3% of which Japan
+13.7%TOTAL7,779-5.2%* France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark
** World less the U.S. and Canada, Western Europe, Japan, Australia and New Zealand
*** Japan, Canada, Australia and New Zealand
(1) +31.0% excluding sales of A/H1N1 vaccines booked in Q1 201First-quarter net sales in Emerging Markets were euro 2,386 million, up 14.6% (+14.1% on a constant structure basis and at constant exchange rates) excluding sales of A/H1N1 vaccines booked in Q1 2010 (euro 355 million), or down 2.6% including A/H1N1 vaccines sales. Sales in Brazil(9) reached euro 308 million, an increase of 32.4% excluding A/H1N1 vaccines sales (down 32.4% including A/H1N1 vaccines). Sales in China(9) grew by 39.2% to euro 204 million led by the performance of Plavix® (+31.1% to euro 65 million). Russia(9) recorded sales of euro 179 million, up 8.5%.
(9) Without Merial sales
Net sales in Japan in the first quarter grew by 13.7% to euro 665 million, sustained by the strong performance of Plavix® (up 28.8% to euro 139 million), Myslee® (up 14.7% to euro 64 million), Lantus® (up 34.8% to euro 26 million), and Allegra® (up 41.1% to euro 186 million) which benefited from a st
Copyright©2010 PR Newswire.
All rights reserved